Basilea Pharmaceutica Ltd. Logo
 
Home
 
 
Search
 
 
 

Basilea Pharmaceutica Ltd. is headquartered in Basel, Switzerland, and listed on the SIX Swiss Exchange (SIX: BSLN). Through its fully integrated research and development operations the company focuses on the development of innovative antibiotics, antifungals and oncology drugs, targeting the medical challenge of resistance and non-response to current treatment options.

 
News
 
 
Language
 
Thursday, October 16. 2014
 
Basel, Switzerland, October 16, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that its partner Astellas Pharma Inc. has filed an amendment to the phase 3 ACTIVE study protocol with the relevant health authorities and ethics committees. The study assesses the investigational antifungal isavuconazole in the treatment of candidemia and other invasive Candida infections.
 
more...
 
Wednesday, October 08. 2014
 
Basel, Switzerland, October 08, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that further subgroup and health economic analyses of data from the phase 3 studies SECURE and VITAL with the investigational antifungal isavuconazole will be presented at the infectious disease conference IDWeek 2014, October 8-12 in Philadelphia (PA), USA.
 
more...
 
Saturday, September 06. 2014
 
Basel, Switzerland, September 06, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) reports today that the U.S. Food and Drug Administration (FDA) has accepted for filing the New Drug Application for isavuconazole submitted by Basilea's license partner Astellas Pharma Inc. The NDA seeks approval of isavuconazole for the treatment of invasive aspergillosis and invasive mucormycosis (also known as zygomycosis) in adults. In accordance with the FDA Prescription Drug User Fee Act (PDUFA), the FDA designated the date of March 8, 2015 for the completion of the review.
 
more...
 
Friday, September 05. 2014
 
Basel, Switzerland, September 5, 2014 - Basilea Pharmaceutica Ltd. (SIX: BSLN) announces today that extensive data will be presented on the anti-fungal isavuconazole and the antibiotics ceftobiprole and BAL30072 at the 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), September 5-9, 2014 in Washington, DC (USA).
 
more...
 
Info
 
 
 

IDSA
Infectious Diseases
Society of America
Doctorfungus